GlassScriptPhysician profile
Paul G Lapoint
NPI 1619064516
$1,567.69
in general payments reported to CMS, 2019-2025
25 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $831 · 2020: $454 · 2021: $282.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $264.22 | 2019-2021 | |
| Therapeuticsmd, INC. | $213.31 | 2019-2021 | |
| Pfizer INC. | $133.54 | 2019-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $119.75 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $117.83 | 2019 | |
| Lupin INC. | $103.41 | 2019-2020 | |
| Amgen INC. | $100.32 | 2019-2021 | |
| Cumberland Pharmaceuticals, INC. | $50.28 | 2019-2021 | |
| Ethicon US, LLC | $47.93 | 2019 | |
| Amag Pharmaceuticals, INC. | $39.96 | 2019 | |
| Evofem Biosciences, INC. | $38.00 | 2020-2021 | |
| Astellas Pharma US INC | $36.72 | 2019 | |
| Myovant Sciences INC. | $36.02 | 2021 | |
| Daiichi Sankyo INC. | $33.10 | 2019 | |
| Covidien LP | $32.82 | 2019-2020 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Hologic Sales and Service, LLC | $31.11 | 2019-2020 | |
| Duchesnay USA Incorporated | $29.50 | 2019 | |
| Aesculap, INC. | $29.26 | 2019-2020 | |
| Exeltis, USA INC. | $26.67 | 2020-2021 | |
| Mayne Pharma Commercial LLC | $16.70 | 2021 | |
| Gilead Sciences, INC. | $15.30 | 2019 | |
| Agile Therapeutics, INC. | $14.29 | 2021 | |
| Sage Therapeutics, LLC | $13.70 | 2020 | |
| Boston Scientific Corporation | $12.84 | 2019 | |
| Smith+Nephew, INC. | $11.11 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Lapoint listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.